PTI5803
Orphan pediatric epileptic syndrome
Phase 2Active
Key Facts
About PannTheraPi
PannTheraPi is a French biotech innovating in neurology with a novel approach targeting the pannexin 1 channel, a mechanism implicated in the root cause of several brain diseases. Its lead asset, PTI5803, has completed a positive Phase 1 trial and is preparing for Phase IIa, initially targeting a high-need pediatric orphan epileptic syndrome. The company is built on strong scientific co-founding expertise in neuroglial biology and epilepsy, positioning it to potentially address a broad range of neurological and psychiatric conditions with new chemical entities.
View full company profile